CRISPR Therapeutics AG (NASDAQ: CRSP) is 62.07% higher on its value in year-to-date trading and has touched a low of $38.94 and a high of $86.95 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRSP stock was last observed hovering at around $67.20 in the last trading session, with the day’s loss setting it -1.32%.
Currently trading at $65.88, the stock is 12.65% and 28.20% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.18 million and changing -1.96% at the moment leaves the stock 19.75% off its SMA200. CRSP registered 20.42% gain for a year compared to 6-month loss of 18.62%. The firm has a 50-day simple moving average (SMA 50) of $37.65 and a 200-day simple moving average (SMA200) of -$7.01.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The stock witnessed a 33.28% gain in the last 1 month and extending the period to 3 months gives it a 31.65%, and is 2.28% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.09% over the week and 6.50% over the month.
CRISPR Therapeutics AG (CRSP) has around 458 employees, a market worth around $5.31B and $100.30M in sales. Distance from 52-week low is 69.18% and -24.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.90%).
CRISPR Therapeutics AG (CRSP) Analyst Forecasts
The EPS is expected to shrink by -278.00% this year
CRISPR Therapeutics AG (CRSP) Top Institutional Holders
The shares outstanding are 78.68M, and float is at 77.23M with Short Float at 17.09%.
CRISPR Therapeutics AG (CRSP) Insider Activity
A total of 36 insider transactions have happened at CRISPR Therapeutics AG (CRSP) in the last six months, with sales accounting for 21 and purchases happening 15 times. The most recent transaction is an insider sale by Kulkarni Samarth, the company’s Chief Executive Officer. SEC filings show that Kulkarni Samarth sold 25,000 shares of the company’s common stock on Apr 25 at a price of $50.67 per share for a total of $1.27 million. Following the sale, the insider now owns 0.39 million shares.
CRISPR Therapeutics AG disclosed in a document filed with the SEC on Mar 29 that Kulkarni Samarth (Chief Executive Officer) sold a total of 25,000 shares of the company’s common stock. The trade occurred on Mar 29 and was made at $44.46 per share for $1.11 million. Following the transaction, the insider now directly holds 0.39 million shares of the CRSP stock.
Still, SEC filings show that on Feb 27, Kulkarni Samarth (Chief Executive Officer) disposed off 25,000 shares at an average price of $48.25 for $1.21 million. The insider now directly holds 375,988 shares of CRISPR Therapeutics AG (CRSP).
CRISPR Therapeutics AG (CRSP): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -49.20% down over the past 12 months.